MedCrypt, a healthtech cybersecurity startup founded near San Diego, has raised $750,000 in a seed financing round led by Safeguard Scientifics (NYSE: SFE), a private equity fund in suburban…
[[Click headline to continue reading.]]
GenomeDx Adds Multiple Leading Cancer Centers to Its Proprietary Genomics Resource Information Database Platform (Decipher GRID)
SAN DIEGO, Sept. 13, 2016 /PRNewswire/ — GenomeDx Biosciences today announced that it has expanded access to its Decipher Genomics Resource Information Database (Decipher GRID®) to a new group of leading cancer centers, allowing them to join the existing Decipher GRID network. The new group of centers includes the Glickman Urological and Kidney Institute at Cleveland Clinic, Tulane Cancer Center, Chesapeake Urology, University of Michigan Cancer Center, University of Maryland Medical Center and Rush University Medical Center. Decipher GRID is a cloud-based genomic expression database that provides participating partners with access to genomic information of patients diagnosed with and treated for urological cancer.
“Accessing Decipher GRID will give us the ability to obtain expansive genomic information and share new insights, allowing us to enhance our application of genomics to the management of our patients with urologic cancers,” said Eric Klein, M.D., chairman of the Glickman Urological and Kidney Institute at Cleveland Clinic. “We look forward to being actively involved in advancing the use of genomic information to deliver better care for our patients.”
“Having access to this database will help us to compare genomic data among patients and will help researchers and clinicians share insights, data and research opportunities that ultimately will benefit our patients during their fight against cancer,” said Leslie Deane, M.D., associate professor of urology at Rush University Medical Center in Chicago.
“GenomeDx has built a tremendous genomic repository in GRID, and expanding our collaborative efforts with these leading cancer centers will allow us to marry the power of genomic information with prospective clinical outcomes for patients,” said Doug Dolginow, M.D., chief executive officer of GenomeDx Biosciences. “We believe as the data sharing capabilities and collaboration enabled by Decipher GRID are increasingly embraced by leading cancer centers and others within the urology and oncology communities, Decipher GRID will facilitate insights on a new scale and help drive important discoveries about urologic cancers.”
Decipher GRID has been the foundation of more than 45 clinical studies relating to GenomeDx’s Decipher® Prostate Cancer Classifier products, published in collaboration with researchers from more than 55 cancer centers in the United States. GenomeDx believes the collaborative benefits and contributions provided by these cancer centers and other contributors to Decipher GRID can accelerate genomic discoveries within the urologic cancer community and help translate genomic solutions into clinical applications at a rapid pace.
About Decipher® Prostate Cancer Classifier Tests
Our Decipher Prostate Cancer Classifier tests currently include Decipher Biopsy and Decipher Post-Op. These commercially available genomic tests provide an assessment of tumor aggressiveness based on the patient’s unique genomic profile. Decipher Biopsy is indicated for men with localized prostate cancer after biopsy diagnosis and Decipher Post-Op is indicated for men after prostate removal surgery. The Decipher tests are used by physicians to stratify patients into more accurate risk groups to better determine which patients will likely benefit from additional treatment and which will not, thereby enabling improved decision-making and helping low-risk patients avoid unnecessary treatments that have serious adverse side effects and result in unnecessary costs to the healthcare system. Studies of thousands of patients from leading cancer centers, published in multiple peer-reviewed journals, demonstrate that the Decipher tests can more accurately predict disease aggressiveness than traditional clinical measures, such as PSA and Gleason score. Decipher Post-Op is covered by Medicare and by a number of private payors and preferred provider organizations representing, together with Medicare, about 70% of the approximately 66 million adult men in the United States age 40 or older who are at increased risk of being diagnosed with prostate cancer.
About Decipher GRID®
Our Decipher Genomics Resource Information Database (Decipher GRID) is a genomic expression database that provides a foundation for open and interactive research collaboration and knowledge creation. Decipher GRID is a rapidly growing database that contains genomic profiles of thousands of patient tumors, and constitutes what we believe to be the world’s largest shared, clinically-annotated genomic expression database in urologic cancer as well as one of the world’s largest global RNA expression databases utilizing cloud-based analytics. We believe Decipher GRID gives rise to new opportunities for information technology-enabled genomic solutions and enables us to more rapidly discover, develop, commercialize and drive the adoption of our existing and new genomic tests. Through Decipher GRID, GenomeDx is building a suite of genomic tests in urologic cancer that we believe will allow us to achieve our goals of reducing costs to the healthcare system and improving patient lives, from screening through late-stage therapy.
About GenomeDx Biosciences
GenomeDx Biosciences uses the power of collaborative genomics to transform the management and treatment of cancer patients. GenomeDx has built Decipher GRID, a large genomics database in urologic cancer that provides a foundation for open and interactive research collaboration and knowledge creation. Using Decipher GRID to analyze vast amounts of genomic data, GenomeDx develops and commercializes proprietary clinical tests that are intended to provide more accurate and useful diagnostic information than both traditional diagnostic tools and existing genomic tests. GenomeDx’s Decipher Biopsy and Decipher Post-Op are commercially available prostate cancer genomic tests that provide an assessment of tumor aggressiveness based on a patient’s unique genomic profile. GenomeDx is headquartered in Vancouver, British Columbia and has offices in San Diego, California.
Learn more at www.GenomeDx.com
SOURCE GenomeDx Biosciences
Sorrento Appoints Miranda Toledano As Executive Vice President of Corporate Development, and President of LA Cell
SAN DIEGO, Sept. 13, 2016 /PRNewswire/ — Sorrento Therapeutics, Inc. (NASDAQ: SRNE), an antibody-centric, clinical stage biopharmaceutical company developing new treatments for cancer, inflammation and autoimmune diseases, today announced that Miranda Toledano has been appointed Executive Vice President of Corporate Development of Sorrento and President of LA Cell, Sorrento’s Joint Venture with City of Hope.
“We are very excited that Miranda has joined our executive team,” said Dr. Henry Ji, President & CEO of Sorrento. “Miranda brings a unique combination of fundamental knowledge and transactional experience in our key therapeutic areas which will be instrumental in crafting Sorrento’s corporate strategy and accelerating our goals for LA Cell.”
Ms. Toledano joins Sorrento with 18 years of principal investment, financing and strategic advisory experience in the biopharmaceutical sector. Since 2012, Miranda served as Head of Healthcare Investment Banking at MLV & Co., now an FBR company, where she completed over 110 IPO and follow on equity offerings totaling over $4 billion in aggregate value. Prior to joining MLV, Miranda served in the investment group of Royalty Pharma where she focused on acquiring best in class biologic therapeutics targeting oncology, auto-immune and neurodegenerative indications. From 1998 to 2003, Miranda served as a Senior Manager at Ernst & Young (Israel) where she established the Life Sciences Corporate Finance group. Miranda received a BA in Economics from Tufts University and an MBA in Finance and Entrepreneurship from the NYU Stern School of Business.
“I am thrilled to be joining Sorrento at this critical juncture in its history. Sorrento has amassed world class capabilities in generating highly differentiated, novel antibody and cell based product candidates which are poised to make a real difference across critical indications where patients are underserved. LA Cell’s platform is disruptive in that it uniquely enables the penetration of large molecules such as antibodies, peptides, and modified DNA into disease cells. We are looking to apply this technology to specifically modulate formerly “undruggable” targets known to the evolution of cancer, infectious and metabolic diseases.”
About Sorrento Therapeutics, Inc.
Sorrento is an antibody-centric, clinical stage biopharmaceutical company developing new treatments for cancer, pain management, inflammation and autoimmune diseases. Sorrento’s lead products are late-stage biosimilar and biobetter antibodies, RTX for intractable cancer pain, as well as clinical CAR-T and CAR-NK therapies targeting solid tumors.
This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sorrento Therapeutics, Inc. and its subsidiaries under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding the expectations for Sorrento’s and its subsidiaries’ technologies and collaborations; Sorrento’s ability to leverage the expertise of its employees and partners to assist the company in the execution of its strategies; and Sorrento’s prospects. Risks and uncertainties that could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: risks related to Sorrento’s and its subsidiaries’ technologies and prospects; risks related to seeking regulatory approvals and conducting clinical trials; and other risks that are described in Sorrento’s most recent periodic reports filed with the Securities and Exchange Commission, including Sorrento’s Annual Report on Form 10-K for the year ended December 31, 2015, as amended, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release except as required by law.
Sorrento® and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.
All other trademarks and trade names are the property of their respective owners.
© 2016 Sorrento Therapeutics, Inc. All Rights Reserved.
SOURCE Sorrento Therapeutics, Inc.
UC San Diego Among Top 10 Best Public Universities in Nation, According to U.S. News & World Report
The University of California San Diego is ranked the 10th best public university in the nation by the U.S. News & World Report Best Colleges guidebook, released today. For more than a decade, the publication has included UC San Diego in its list of the nation’s top 10 public universities.
Solutions for biotechnology and pharmaceutical companies, scientific research. BioMed Realty , L.P ., with its….From careerbuildergulf – Tue, 13 Sep 2016 01:48:32 GMT – View all San Diego jobs
Experienced in GAMP 5 and 21 CFR Part 11. Carefully analyze and document test results. Coordinate and participate in development, testing, and implementation of…From Illumina, Inc. – Tue, 13 Sep 2016 01:45:51 GMT – View all San Diego jobs
Relationships delivers, optimal real estate solutions for biotechnology and. BioMed Realty , L.P ., with its trusted expertise and valuable….From careerbuildergulf – Tue, 13 Sep 2016 01:44:43 GMT – View all San Diego jobs
Scientist to work for a leading San Diego biotechnology company. BioPhase Solutions specializes in recruiting top talented professionals for San Diego’s…
From BioPhase Solutions – Tue, 13 Sep 2016 01:23:49 GMT – View all San Diego jobs
DESCRIPTION OF POSITION RESPONSIBILITIES: To perform this job successfully, an individual must be able to perform each essential duty satisfactorily. The requirements listed below are representative of basic knowledge, skills, and/or abilities requir […
Hologic, Inc. is a leading developer, manufacturer and supplier of premium molecular diagnostic products and services that are used to diagnose human diseases, screen donated human blood and to aid in biomedical research. Hologic is also a leader in […